High-Dose Flu Shot Outperforms Standard Dose for Older Adults in Pivotal Pooled Analysis

New evidence from the largest influenza vaccine trial ever conducted shows high-dose vaccine provides 8.8% better protection against flu-related hospitalizations in adults 65 and older.

June 11, 2026 | Kolkata, West Bengal

A landmark pooled analysis of two massive randomized trials has confirmed that the high-dose influenza vaccine provides superior protection against hospitalization compared to the standard-dose version for older adults. The findings offer crucial evidence for healthcare providers and seniors navigating flu vaccination decisions this season.

The FLUNITY-HD study, published in The Lancet in October 2025, analyzed data from 466,320 adults aged 65 and older across Denmark and Spain during the 2022–2025 influenza seasons. The research demonstrated that the high-dose inactivated influenza vaccine (HD-IIV) reduced hospitalizations for influenza or pneumonia by 8.8% compared to the standard-dose vaccine.

Key Findings That Matter for Older Adults

The analysis revealed compelling benefits across multiple health outcomes. Hospitalizations for influenza or pneumonia occurred in 0.56% of high-dose vaccine recipients versus 0.62% of standard-dose recipients. While this absolute difference appears modest, the public health impact at a population level could be substantial given the extreme vulnerability of this age group.

The high-dose vaccine showed particularly strong protection against laboratory-confirmed influenza hospitalizations, demonstrating a 31.9% relative vaccine effectiveness. Additionally, recipients experienced lower rates of cardiorespiratory disease hospitalizations (6.3% relative reduction) and all-cause hospitalizations (2.2% relative reduction).

“We’re seeing consistent evidence that the high-dose vaccine provides meaningful incremental protection for older adults,” said Dr. Tor Biering-Sørensen, MD, PhD, the study’s lead investigator from Copenhagen University Hospital–Herlev and Gentofte in Denmark. “This is particularly important because adults 65 and older face disproportionately higher risks of severe flu complications.”

Understanding the High-Dose Advantage

The high-dose influenza vaccine contains four times the amount of hemagglutinin antigen (60 μg per strain) compared to a standard-dose vaccine (15 μg per strain). Hemagglutinin is the specific protein on the surface of the flu virus that triggers the human immune system to create protective antibodies.

Think of the antigen as a training simulation for your immune defense force. The standard-dose vaccine provides a basic training routine. The high-dose vaccine delivers a much more intense, amplified simulation. This extra biological stimulation helps overcome immunosenescence, which is the natural, gradual weakening of the immune system that occurs as people age.

According to data from the Centers for Disease Control and Prevention (CDC), individuals aged 65 and older routinely bear the heaviest burden of severe influenza. In typical flu seasons, this demographic accounts for 70% to 85% of all flu-related deaths and up to 70% of flu-related hospitalizations. Because standard flu vaccines do not always generate a robust immune response in older bodies, enhanced options are critical. The high-dose formulation, marketed as Fluzone High-Dose Quadrivalent (or Efluelda in European markets), has been preferentially recommended for this age group by the CDC’s Advisory Committee on Immunization Practices (ACIP) since 2022.

Reading the Conflicting Trial Data

The FLUNITY-HD pooled analysis brings much-needed clarity to the medical community after two individual trials initially produced seemingly conflicting results.

• The GALFLU Trial (Spain): Showed an impressive 23.7% relative vaccine effectiveness against influenza or pneumonia hospitalizations.

• The DANFLU-2 Trial (Denmark): Involved a much larger cohort of 332,438 participants but found only a 5.9% reduction in hospitalizations—a figure that was not statistically significant on its own.

By combining the raw data from both trials into a single pooled analysis, scientists effectively increased the statistical power of the data, allowing them to see the true mathematical trend. The researchers discovered that the high-dose vaccine was 44% more effective against flu-only hospitalizations specifically within the Danish trial group. This suggests that while the vaccine is highly effective at stopping influenza itself, its statistical impact can appear diluted when combined with broader clinical diagnoses like generalized pneumonia, which can be caused by many other pathogens.

Who Benefits Most: Age Matters

The evidence suggests that the high-dose vaccine’s advantage becomes most pronounced as individuals advance in age. A separate 2025 systemic review examining real-world effectiveness noted that the superiority of the high-dose shot is most consistent and distinct in individuals aged 75 and older. For the younger-old demographic (ages 65 to 74), the statistical difference between the standard and high-dose options is narrower.

In the FLUNITY-HD pooled analysis, the high-dose vaccine was 54% more effective against infection among adults aged 80 and older. This age-stratified benefit aligns perfectly with our understanding of human biology: immunosenescence accelerates significantly after age 75, making the extra antigen payload even more vital for the very elderly.

Safety Profile and Side Effects

Importantly, the FLUNITY-HD analysis confirmed that the high-dose vaccine maintains a safety profile highly similar to the standard dose. There was no observed increase in serious adverse events or systemic safety failures. For instance, out of nearly 6,000 serious adverse events recorded during the trial periods, the events split almost evenly: 49.7% occurred in the high-dose group and 50.3% occurred in the standard-dose group.

However, consumers should anticipate a higher rate of mild, temporary side effects. Because the high-dose vaccine deliberately provokes a stronger immune reaction, it frequently causes more localized symptoms during the first week following the injection.

Common Mild Side Effects

• Soreness, redness, or swelling at the injection site

• Headache

• Muscle aches and joint stiffness

• Mild fatigue or low-grade lethargy

These responses are non-dangerous signs that the immune system is actively responding to the vaccine components and building antibodies.

Practical Implications for Patients and Providers

To help clinicians understand the absolute real-world benefit of these shots, researchers calculated the Number Needed to Vaccinate (NNV)—the number of people who must receive a treatment for one person to benefit directly from it.

While an NNV of 1,839 to prevent a single flu hospitalization sounds high, across an entire nation’s elderly population, deploying the high-dose vaccine saves thousands of hospital beds and millions of dollars in intensive care costs.

However, medical professionals must weigh these figures against economic realities. “The high-dose vaccine carries a significantly higher financial cost per dose, which can impact local health budgets and cost-effectiveness models, particularly for the younger 65-74 age bracket where the standard dose still provides excellent protection,” noted an independent public health analyst.

For the current 2025–2026 flu season, the CDC continues to stand by its guidance: older adults should receive an enhanced vaccine if available. This includes either the high-dose vaccine or an adjuvanted flu vaccine (Fluad), which uses an added ingredient called an adjuvant to boost the body’s immune response instead of extra antigens.

Limitations and What Remains Uncertain

While the FLUNITY-HD study provides robust data, independent experts point out a few critical caveats. First, the absolute risk reduction is quite small (a 0.06% absolute difference in influenza/pneumonia hospitalizations). This means that on an individual level, the vast majority of seniors will remain out of the hospital regardless of which of the two vaccines they receive.

Second, the trials were funded entirely by Sanofi, the pharmaceutical company that manufactures Fluzone High-Dose/Efluelda. While the study protocols dictate that the manufacturer had no direct role in managing data or conducting the trial analysis, industry-funded research always invites closer scrutiny.

Finally, real-world effectiveness is heavily reliant on how well scientists predict circulating virus strains months in advance. If the strains selected for the seasonal vaccine do not match the dominant strains actively spreading in winter, the real-world advantage of the high-dose version over the standard-dose version may decrease.

The Bottom Line for Older Adults

The overarching consensus among infectious disease experts is clear: getting vaccinated with any approved flu shot is vastly superior to skipping vaccination entirely. Standard-dose flu shots remain highly accessible, reliable, and effective counter-measures against severe illness.

For adults aged 65 and older—and most crucially, those over 75 or living with chronic conditions like diabetes—the high-dose vaccine is the optimal choice and should be requested when visiting pharmacies or clinics. However, health professionals emphasize that patients should never delay their seasonal shot if a high-dose vaccine is temporarily out of stock. Securing immediate protection via a standard-dose shot is always preferable to leaving oneself unprotected while waiting for premium inventory to arrive.

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References

• https://www.medscape.com/viewarticle/high-dose-flu-shot-beats-standard-dose-older-adults-2026a1000jgr